In situ tumor cell killing by the herpes simplex virus thymidine kinase (HSVtk) gene can effectively prime antitumor T-cell responses, at least in part through local induction of a pro-inflammatory environment. Therefore, we reasoned that tumor-associated HSVtk expression would significantly enhance the efficacy of adoptive T-cell transfer (ACT) of (tumor) antigen-specific T cells into tumor-bearing hosts. When B16ovaHSVtk tumors were treated with ganciclovir (GCV), along with suboptimal numbers of activated OT-1T cells, complete tumor regressions were observed where GCV, or ACT, alone was completely ineffective. To our surprise, analysis of regressing tumors showed no increases in intratumoral OT-1T cell trafficking. However, the intratumoral percentages of both OT-1 and endogenous natural killer (NK) cells were substantially increased over controls. Depletion of endogenous NK cells abrogated the efficacy of the combination therapy and reduced the percentages of interferon-g (IFNg)-secreting OT-1T cells in mice that received combined therapy to levels similar to those of control mice. These data suggest that even relatively low levels of gene transfer of suicide genes into tumors may have therapeutic value as an adjuvant for other T-cell therapies, by providing immunological signals that support T-cell activation and expansion in vivo.
Introduction
Adoptive T-cell transfer (ACT) for cancer is one of the most effective immunotherapies against melanoma, with a 30-50% objective clinical response rate. [1] [2] [3] [4] However, efficacy is limited by suboptimal T-cell survival, memory differentiation, trafficking and effector functions at the tumor site. 5, 6 In this respect, increased T-cell survival, effector functions and memory differentiation have been achieved by host lymphodepletion, changes in the culture conditions and by further vaccination after ACT. 2, 7, 8 Gene transfer, to either the tumor cells or the T cells themselves, 4 offers the potential for further improvements by altering the specificity and/or longevity and effector functions of the T cells, or by modifying the tumor microenvironment. 9 Intratumoral expression of the herpes simplex virus thymidine kinase (HSVtk) gene leads to cell killing on administration of the prodrug ganciclovir (GCV). [10] [11] [12] We, and others, have demonstrated that HSVtk-mediated tumor cell death in vivo can be potently immunogenic through the induction of immunostimulatory proteins such as hsp70 13, 14 and of Th-1 inflammatory cytokines. [15] [16] [17] [18] This response has been observed in both preclinical and clinical studies. [19] [20] [21] However, the clinical outcome of HSVtk/GCV suicide gene therapy alone in patients has been disappointing, 20, [22] [23] [24] [25] and a recent Phase III study reported no survival benefit of HSVtk/GCV adjuvant therapy after surgery. 26 Taken together, these results suggest that with current vector efficiencies 27 the optimal therapeutic value of suicide gene-mediated tumor killing is likely to be realized as one component of novel combination therapies.
One of the most striking observations regarding the effects of HSVtk-mediated tumor killing is that GCV treatment of B16-HSVtk+ve tumors generates a potently immunostimulatory tumor microenvironment, associated with accumulation of host-derived leukocytes and the induction of a Th-1 inflammatory response. 15 Therefore, we reasoned that local HSVtk-mediated tumor cell killing would be an effective method by which the efficacy of ACT could be significantly enhanced in vivo. This hypothesis derives from several observations. First, it has been shown that immunosuppressive cells or factors expressed within established tumors, 9 such as transforming growth factor-b (TGF-b), can both inhibit the trafficking of activated T cells to the site of tumor growth and also the ability of those T cells to exert their effector functions once there. 28 Therefore, it seems likely that the pro-inflammatory environment of HSVtkmediated killing would help to reverse the immunosuppressive milieu normally associated with established tumors. 9 The consequences of this could be manifested in either, or both, of the following two ways. First, the pro-inflammatory environment at the tumor site induced by HSVtk killing might serve as a potent means to attract more of the adoptively transferred antigen-specific T cells to the tumor, compared to tumors with no ongoing cell killing. 29 Alternatively, or additionally, the activated T cells, which reach the site of antigen expression at the tumor may be more active in terms of expression of effector functions such as perforin-mediated target cell lysis and interferon-g (IFN-g) expression. 28 Second, we recently delivered retroviral vectors encoding HSVtk to disseminated B16ova metastases by adsorbing retroviral particles to the surface of activated OT-1T cells. 30, 31 In these studies, the T-cell-mediated delivery of the HSVtk gene, followed by GCV therapy, significantly enhanced the antitumor efficacy of an otherwise ineffective ACT. 30 However, using viral vectors encoding the GFP gene, we observed that only between 5 and 10% of tumor cells, which were not killed by direct cytolytic effects of OT-1T cell therapy in vivo, were transduced by the vectors delivered by the T cells. Therefore, it seemed unlikely that this modest level of suicide gene transfer into lung metastases, combined solely with the low levels of tumor cell killing by the suboptimal dose of OT-1 cells, could fully explain the extensive therapeutic effects that we observed in vivo. Moreover, in lymphodepleted hosts, we observed a dramatic in vivo expansion of, and repopulation of the mice, with the adoptively transferred T cells but only following HSVtk-mediated killing of the original metastases. 30 These data suggest that HSVtk-mediated killing of B16ova tumors significantly enhances the activity of adoptively transferred antigen-specific T cells. However, it is unclear from these studies whether these beneficial interactions occur through increased attraction of the T cells to the tumors, enhanced activation of their cytolytic properties once there and/or increased expansion of their numbers through in vivo priming of antigen-specific responses.
We show here that suicide gene therapy with HSVtk/ GCV can be very effectively combined with ACT to generate therapies that are significantly better than either alone. To our surprise, given the observation that HSVtk killing of B16 tumors generates an immunostimulatory tumor microenvironment, we could not detect increased trafficking of absolute numbers of adoptively transferred T cells to GCV-treated tumors. In contrast, the increased antitumor effect produced by the combination of adoptive transfer and immunostimulatory HSVtk/GCV tumor cell killing is strictly dependent on host-derived NK cell effectors and increased activity of the T cells at the tumor site. These studies provide a rationale for further experiments aimed at delivering vectors expressing HSVtk in combination with ACT, where HSVtk gene transfer may be more valuable in an immunological adjuvant capacity than necessarily as a direct cytotoxic agent.
Results
B16ovaHSVtk clones are sensitive to in vitro GCVmediated toxicity and are recognized by activated ova-specific CD8 OT-1T cells B16ova melanoma cells, expressing the chicken ovalbumin model antigen (ova), were transduced with the Moloney murine leukemia virus retroviral vector pBabepuro expressing HSVtk. Stable clones were selected and tested for their sensitivity to GCV-induced cell death. In vitro GCV (5 mg ml
À1
) treatment of HSVtktransduced B16ova cells induced cell killing as assessed by decreased cell numbers and annexin V/PI (AnnV/PI) staining (Figure 1a and b) , whereas cell lines transduced with vector control (B16ovaPuro-3,5) showed no GCVmediated toxicity (Figure 1a and b) .
Expression of the model antigen chicken ovalbumin was verified by Western blot and reverse transcriptionpolymerase chain reaction (RT-PCR) analysis (data not shown). To assess antigen presentation and T-cell recognition of B16ova cells, Cr 51 release assays were performed using ex vivo-activated, ovalbumin-specific CD8+ T cells from OT-1 transgenic mice. OT-1T cellmediated lysis of B16ovaHSVtk and B16ovaPuro clones was equivalent to that of B16ova parental cell line, indicating that antigen expression, and presentation were unaltered in these cell lines (Figure 1c ). B16ovaHSVtk-2 and B16ovaPuro-3 cell lines, hereafter B16ovalHSVtk and B16ovaPuro respectively, were selected for further studies as representative clones.
In vivo GCV-mediated killing induces an immunostimulatory tumor microenvironment
B16ovaHSVtk tumors were established subcutaneously in C57BL/6 mice and GCV (50 mg kg
À1
) was administered intraperitoneally for 5 consecutive days. As previously published by us, 15 RT-PCR analysis of tumors at different times during GCV therapy showed induction of the inflammatory cytokines peaking at day 7 after the first treatment with GCV (data not shown). Sections of tumors undergoing PBS treatment indicated only low levels of cellular death/degeneration/apoptosis/necrosis (o10%), whereas tumors from GCV-treated mice scored consistently higher levels (10-25%) (Figure 2a ). In addition, increased leukocyte infiltration was observed in GCV-treated mice, consisting mainly of small aggregates of mononuclear cells (Figure 2a) . These data show a strong correlation between cytokine induction, tumor cell death and leukocyte infiltration induced by the GCV therapy, reaching peak levels by day 7 after initiation of the GCV treatment.
We further studied the phenotype of the leukocytes present in the tumor microenvironment of GCV-treated mice. The analysis of different leukocyte subpopulations at day 8 after GCV initiation showed that only NK1.1+ cells and Gr-1+ cells were present in higher percentages in GCV-treated mice (Figure 2b ). We believe that the GR-1+ cells probably represent a population of neutrophils, because analysis with mac-3+ staining, which is more specific for macrophages, did not show any increased percentage of positive cells. We cannot, however, exclude the possibility that these GR-1+ cells also include CD11b+GR-1+ immature myeloid cells. None of the other cell types studied, including T cells (CD3e+), dendritic cells (CD11c+) and macrophages (mac-3+) were present at significantly different levels in GCVtreated tumors compared to PBS-treated tumors (data not shown). These data indicate that GCV therapy of B16ovaHSVtk tumors in vivo induces intratumoral inflammatory cytokines and increases the percentages of NK1.1+ and Gr-1+ cells at the tumor.
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Suboptimal ganciclovir therapy delays tumor progression
We developed a suboptimal regimen of GCV treatment in vivo to avoid eradication of the B16ovaHSVtk tumors and to allow any additional beneficial effects of adoptive T-cell therapies to become apparent. Mice bearing 10-day-established B16ovaHSVtk tumors were treated with GCV intraperitoneally (50 mg kg
À1
) for 5 consecutive days. 30 This produced an observable delay in tumor growth, starting on the last day of GCV therapy, although tumors grew progressively in PBS-treated mice (Figure 3a ). This delay lasted for about 10 days after which tumors grew progressively again in 90-100% mice. Therefore, this model resembles a likely clinical situation where levels of HSVtk gene transfer can be achieved that control but do not eradicate tumors.
Adoptive transfer of ex vivo-activated T cells in combination with GCV therapy leads to tumor eradication
We used this subcutaneous model to test the antitumor efficacy of ACT in combination with HSVtk/GCV suicide gene therapy. B16ovaHSVtk tumors were allowed to establish for 10 days, followed by GCV or PBS treatment for 5 days, and combined with infusion of two separate doses of 5.0 Â 10 6 ex vivo-activated OT-1T cells. Administration of 5.0 Â 10 6 -activated OT-1T cells into GCVtreated mice led to tumor rejection and 90% survival (Figure 3b , Po0.0001 compared with either GCV, or OT-1 alone). ACT alone, or GCV therapy alone, did not have any long-term survival benefit, but their survival was prolonged compared to PBS-treated mice (Figure 3b) . Therefore, this model reiterates our previous findings 30 Figure 1 B16ova-derived clones expressing HSVtk are sensitive to GCV-mediated cell death and are recognized by ova-specific OT-1T cells. (a) B16, B16ova and B16ova-derived clones were plated in 96-well plates in triplicate at 1.0 Â 10 4 cells well À1 in the presence of GCV (5 mg ml À1 ). MTT proliferation assay was performed at the indicated time. Absorbance was read at 550 nm after all samples were treated. (b) B16ovaPuro-3 and B16ovaHSVtk-2 were plated on six-well plates at 2.0 Â 10 5 cells ml À1 and treated with GCV (5 mg ml
À1
). At 72 h, supernatant and adherent cells were harvested and cell death was determined by Annexin V/PI staining. (c) A Cr 51 cytotoxic assay was performed using 5 days ex vivo-activated OT-1T cells. B16-and B16ova-derived clones were labeled with 100 mCi of Cr 51 and co-cultured with activated OT-1T cells at the indicated ratio in triplicate. After 4 h incubation, supernatants were harvested and analyzed for Cr 51 using Lumaplates.B, B16; &, B16ova; ., B16ovaHSVtk-1; mK, B16ovaHSVtk-2; ,, B16ovaPuro-3 and J, B16ovaPuro-5. *Po0.05 by two-sample unequal variance Student's t-test analysis. Experimental data were derived from three samples per group and results shown are typical of multiple different experiments. Error bars represent standard deviations.
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L Sanchez-Perez et al that, under appropriate dosage conditions, a combination of HSVtk suicide gene therapy with ACT performs significantly better than either treatment alone.
Low-dose combination therapy is enhanced in RAGÀ/À mice
Many gene therapies, 32 as well as adoptive transfer approaches, 33 benefit from the absence of host lymphocytes. To mimic this, we performed the combination therapy in RAGÀ/À mice, which lack T and B cells but maintain intact NK homeostasis. Two doses of 5.0 Â 10 6 OT-1T cells, in combination with HSVtk/GCV suicide gene therapy, were largely curative in wild-type mice, but doses lower than that failed to provide any therapeutic benefit when compared to mice that only received ACT (Figure 3c ). Therefore, we used 2.5 Â 10 6 OT-1T cells for these studies so that we would be able to detect any enhancement of therapy on the RAGÀ/À background. Under these conditions, the combination therapy significantly prolonged survival in RAGÀ/À mice ( Figure 3d , Po0.0001 OT-1 plus GCV-treated mice compared to either GCV or OT-1 alone). In addition, mice treated with GCV alone displayed an identical survival advantage to that seen in wild-type mice, indicating that GCV antitumor effects are independent of host T or B cells (Figure 3d ). These data indicate that HSVtk/GCV gene therapy, in combination with adoptive transfer, Figure 2 In vivo GCV-mediated killing induces an immunostimulatory tumor microenvironment. (a) GCV or PBS was given once intraperitoneally for 5 consecutive days to mice bearing 10-day-established B16ovaHSVtk tumors. Tumors were harvested on days 3, 5 and 7 after initiation of the treatment and fixed in formalin and processed for paraffin sections. H&E slides corresponding to day 3, 5 and 7 after initiation of GCV or PBS treatment as shown. An independent pathologist read the H&E slides and determined the level of necrosis and leukocyte infiltrates. (b) Flow cytometry analysis was performed on tumors extracted on day 8 after GCV (50 mg kg À1 ) or PBS initiation to study leukocyte infiltrates. Tumors were harvested, placed in media on ice and single cells suspensions were made and analyzed by flow cytometry analysis for different makers to study leukocytes present in the tumor microenvironment: NK1.1+ (NK and NK T cells) and Gr-1+ (granulocytes). Po0.05, by two-sample unequal variance Student's t-test analysis. &, PBS; ', GCV. Experimental data were obtained from three mice per group and are representative of two separate experiments. Error bars represent standard deviations. Arrows point at areas of leukocyte infiltration.
Suicide gene therapy enhances adoptive T-cell therapy L Sanchez-Perez et al does not require endogenous T cells to be effective and can be more successful in host in which T and B cells are absent, consistent with our results in the model of T cell-mediated vector delivery. 30 Antigen expression is required for combination therapy to be effective
We investigated whether HSVtk/GCV therapy, in combination with ACT, could induce regression of B16HSVtk tumors, which lack the ova expression but express HSVtk. As expected, mice bearing 10-day-established B16HSVtk tumors,treated with GCV, demonstrated increased survival times compared with PBS-treated mice (Figure 3f ). However, OT-1T cells ACT did not alter tumor growth or survival times in either PBS-or GCV-treated mice (Figure 3f ). Taken together, these data demonstrate that T-cell antigen recognition is necessary for the efficacy of ACT and HSVtk/GCV combination therapy.
GCV treatment of B16ovaHSVtk-bearing mice does not enhance T-cell trafficking but increases the percentage of OT-1T cells and NK1.1 cells at the tumor site As inflammatory cytokines have been observed to be induced in HSVtk/GCV dying tumors, 15 and to enhance the recruitment of activated T cells, we hypothesized that adoptively transferred ex vivo-activated OT-1T cells would be recruited to GCV-treated B16ovaHSVtk tumors Suicide gene therapy enhances adoptive T-cell therapy L Sanchez-Perez et al more efficiently than to PBS-treated mice. However, B16ovaHSVtk tumor-bearing mice treated with GCV showed no significant difference in the recruitment kinetics of CM-DiI (carbocyanine membrane-1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine perchlorate)-labeled OT-1T cells to the tumor site compared to PBS-treated mice (Figure 4a ) in that similar absolute numbers of cells reached the tumor site, with identical kinetics, in both GCV-and PBS-treated mice (Figure 4a ). In contrast, the percentage of intratumoral OT-1T cells, relative to the overall number of cells constituting the tumor, increased in GCV-treated B16ovaHSVtk tumors with time (Figure 4b ). Because of possible confounding factors associated with loss of Cm-DiI label from proliferating cells, we confirmed these results by detecting intratumoral OT-1T cell using an antibody specific for the Va2 chain of the OT-1 transgenic T-cell antigen receptor (TCR). 34 Once again, no increase in absolute numbers of intratumoral OT-1T cells was detected in GCV-treated mice compared to PBS-treated mice, on day 8 after treatment initiation (data not shown). In contrast, an increased percentage of OT-1T cells was detected in GCV-treated mice ( Figure 4c ) consistent with our Cm-DiI results (Figure 4b ).
Simultaneous analysis of NK1.1 cells at the tumor site showed a similarly increased percentage of host-derived NK1.1+ cells in GCV-treated mice that received ACT, when compared to mice that were treated with PBS and OT-1T cells (Figure 4d ). However, differences in absolute numbers were not significant between mice that received ACT plus GCV or PBS control (data not shown). Taken together, these results suggest that despite the induction of an immunostimulatory intratumoral environment by HSVtk/GCV therapy, this does not enhance the kinetics of T-cell trafficking to the tumor site. Nonetheless, in combination with the cytoreductive effects of HSVtkmediated tumor cell killing, higher percentages of OT-1T cells and NK1.1+ cells accumulate at the tumor site.
NK cells are required for the efficacy of the HSVtk/ GCV and adoptive transfer therapy As the absence of NKT cells in RAGÀ/À mice did not adversely affect the efficacy of the combined therapy (Figure 3c) , and because previous studies have shown that endogenous NK cells can be important for adoptive transfer, 35 we performed the therapies in wild-type mice depleted of NK cells by anti-asialo-GM1 treatment. 36 Interestingly, depletion of NK cells altered tumorigenesis of B16ova tumors per se, leading to decreased survival times when compared to wild-type nondepleted mice (Figure 5a , P ¼ 0.0002). NK depletion also slightly, but statistically significantly, decreased the efficacy of GCV therapy alone (Figure 5b , P ¼ 0.0014). These results are consistent with other reports showing the importance of NK cells in immunosurveillance 37 and, to our knowledge, the first to show that NK cells play a role in GCVmediated B16 melanoma tumor-growth delay.
In contrast, the effects of NK cell depletion in combination with ACT were much more marked. Nondepleted mice treated with the combination of GCV and ACT showed significant differences when compared to OT-1T cells alone (Figure 5c , P ¼ 0.0324 OT-1 compared to OT-1+GCV; P ¼ 0.0002 GCV compared to OT-1+GCV). However, no increased survival time was 
Suicide gene therapy enhances adoptive T-cell therapy L Sanchez-Perez et al
observed between NK-depleted groups that received activated ACT plus GCV treatment and mice that received ACT with PBS (Figure 5d , P ¼ 0.1575). These data suggest that host NK cells are critical to the success of the combination of HSVtk/GCV suicide gene therapy combined with ACT.
NK cell depletion reduces the percentages of IFNg+OT-1T cells in mice receiving the combined therapy
Seven days after inititation of GCV/PBS treatment, there was a highly significant increase in the percentage of Va2+CD8+ T cells observed in mice that received ACT plus GCV treatment compared to mice receiving ACT plus PBS (Figure 6a ). Depletion of NK cells abolished this increase (Figure 6a) , consistent with our results in Figure  5 . Similarly, the percentage of IFNg-secreting OT-1T cells was significantly increased in nondepleted mice receiving GCV compared to those treated with PBS (Figure 6b) . However, NK cell depletion also abolished this difference between GCV and PBS treatment mice that received ACT (Figure 6b ). Therefore, NK cells are critical to maintain both increased percentage and activity of intratumoral OT-1T cells in tumors undergoing HSVtk/ GCV-mediated therapy.
Discussion
We describe here a model system that demonstrates that it is possible to obtain considerable synergism between local HSVtk-mediated tumor killing and ACT. To achieve this, we developed a cell line expressing both the HSVtk and ovalbumin genes (B16ovaHSVtk). These cells were sensitive to GCV and were recognized and killed by transgenic OT-1T cells in vitro. We also confirmed that GCV treatment of B16ovaHSVtk tumors generates an immunostimulatory microenvironment characterized by the induction of Th-1 inflammatory cytokines, consistent with our previous studies, as well as those of other groups. [13] [14] [15] [16] However, now we have also extended those findings by showing here that GCV-mediated tumor To investigate whether HSVtk-mediated tumor killing could cooperate with ACT, we developed a suboptimal regimen of GCV treatment of relatively large, 10-dayestablished B16ovaHSVtk tumors, which is, itself, not curative. In this model, GCV administration for 5 days led to a transient tumor growth plateau that lasted B10 days followed by progressive tumor growth. When we treated these 10-day-established tumors (in the absence of GCV) with a suboptimal dose of OT-1T cells, survival of the tumor-bearing mice was prolonged but no cures were produced. In contrast, treatment with both GCV and OT-1T cells significantly enhanced the antitumor efficacy of either treatment alone.
As lymphodepletion has been shown to enhance adoptive T-cell therapy, 4, 33 we first used RAGÀ/À mice that lack B and T cells to test whether the efficacy of combination HSVtk/ACT therapy could also be enhanced. Using adoptive transfer of only 2.5 Â 10 6 OT-1T cells, along with GCV treatment, our results show that the combination therapy conferred enhanced antitumor efficacy in RAGÀ/À mice to a treatment regimen that otherwise is ineffective in wild-type mice. These data indicate that the efficacy of the combination therapy does not rely on endogenous T or B cells, but is highly dependent on the effector functions of the adoptively transferred OT-1T cells. Consistent with this, we confirmed that expression of the target ova antigen recognized by the OT-1T cells is an absolute requirement for therapy. However, HSVtk/GCV treatment of B16ova tumors did not increase the sensitivity of the cells to OT-1 recognition and lysis through upregulation of MHC Class I, B7.1, ICAM or Fas (data not shown). Therefore, although antigen recognition is strictly required for therapy enhancement by HSVtk/GCV in vivo, the contribution of GCV treatment is not mediated by enhancing direct tumor cell recognition and sensitivity to OT-1T cell cytotoxicity.
Our initial hypothesis underpinning this work had been that the pro-inflammatory environment at the tumor site induced by HSVtk killing might serve as a potent means to attract more of the adoptively transferred antigen-specific T cells to the tumor, compared to tumors with no ongoing cell killing. 29 To our surprise, however, trafficking studies showed no differences in OT-1T cell recruitment or accumulation, when measured by absolute numbers in either PBS-or GCV-treated tumors. Levels of T-cell trafficking to tumors might be confounded by the fact that the number of T cells detected within tumors will be a balance between cell trafficking and cell death. We were unable to detect any significant differences between the percentage of Vb2+, AnnexinV+, OT-1T cells in tumors in mice bearing B16ovaHSVtk tumors treated with either GCV or PBS at different time points. These findings suggest that differences in the levels of T-cell death are probably not affecting the absolute numbers of OT-1T cells in the tumor of GCV-or PBS-treated tumor-bearing mice. However, although GCV-treated B16ovaHSVtk tumors did not promote enhanced OT-1T cell recruitment, the relative percentages of transferred OT-1T cells in GCVtreated tumors were significantly increased. We believe, therefore, that one component of the enhanced therapy generated by the combination of HSVtk/GCV and adoptive T-cell therapy is that the cytoreductive effects of HSVtk/GCV killing allow the effective effector:target ratio of cytolytic T cells to tumor cells to be increased locally. 38 Nonetheless, the RAGÀ/À experiments did not rule out the possible involvement of components of the host innate immune response to tumor cell killing. In this respect, we observed an increase in the levels of NK1.1+ cells in tumors of mice treated with both OT-1 and GCV. Our results in RAGÀ/À mice suggested that the NKT cell component of the NK1.1+ cell population was not important in mediating enhanced therapeutic effects of the combined therapy. Therefore, we investigated whether depletion of NK cells would have any adverse effects on therapy in our model. Interestingly, NK cell depletion increased tumorigenesis of the B16ovaHSVtk tumors. GCV therapy still prolonged mice survival times (B8 days) but for shorter periods of time than in nondepleted mice (B11 days). However, depletion of NK cells significantly reduced the efficacy of the combination therapy (OT-1+GCV) to levels indistinguishable from that obtained with OT-1 alone. Most Figure 6 NK cell depletion reduces the percentages of IFNg+OT-1T cells in mice receiving the combined therapy. B16ovaHSVtk tumor-bearing mice were either isotype-treated (n ¼ 3) or NKdepleted (NK-) (n ¼ 3). NK-depleted mice received a total of six injections of anti-asialo-GM1. Mice were injected intraperitoneally 1 day before tumor inoculation (B0.75 mg ml À1 ) and every 5 days afterward, with 20 ml of anti-asialo-GM1 (B0.6 mg mouse À1 ) in a total volume of 100 ml. C57BL/6 mice isotype-treated and NKdepleted were treated with GCV (50 mg kg À1 ) or PBS intraperitoneally once a day for 5 consecutive days. On days 2 and 4 after initiation of GCV or PBS treatment, 5.0 Â 10 6 ex vivo-activated OT-1T cells were infused intravenously. Tumors were harvested on day 8 after initiation of GCV or PBS treatment and submitted to flow cytometry analysis and IFNg intracellular staining. Suicide gene therapy enhances adoptive T-cell therapy L Sanchez-Perez et al significantly, in the absence of NK cells, similar percentages of OT-1T cells accumulated in tumors of mice treated with either GCV or PBS, despite the reduced tumor burden produced by GCV treatment. A corresponding loss of IFNg-secreting OT-1T cells was also observed in terms of overall percentages of the tumor size when NK cells were depleted, compared to when NK cells were present, in GCV-treated animals. These findings correlate well with the failure of the combination therapy to exceed that of ACT alone in NK-depleted mice. We believe that these results provide major explanation for the increased efficacy of the combination therapy over either adoptive T-cell therapy or HSVtk/ GCV suicide gene therapy alone and indicate that the cytoreductive effects of HSVtk/GCV, leading to increased effector:target ratios in the tumor, are unlikely to be the sole component of this enhancement in therapy.
Rather, our findings demonstrate that host NK cell responses, possibly initiated by the HSVtk/GCVinduced immunostimulatory tumor microenvironment, are critical in enhancing the combination therapy over and above that seen with adoptive T-cell therapy alone.
We are currently investigating exactly how hostderived NK cells influence the potency of the combined therapy. Our current model proposes that the inflammatory environment produced by the response of macrophages, and other cells, to HSVtk/GCV-induced cell death in vivo 13, 39 induces the recruitment of NK cells to the tumor site. Subsequent NK cell effector mechanisms 35, 40, 41 might be induced as a result of cytokines, possibly including IFN-g, produced from the OT-1T cells that traffic to the tumors. Similarly, NK effector mechanisms may also play a supportive role in further enhancing the activity of the OT-1 cells at the tumor site, as evidenced by a greater percentage of IFNgsecreting OT-1T cells in mice receiving the combined therapy. Preliminary studies in our laboratory suggest that HSVtk/GCV does not, itself, sensitize tumor cells to NK cell-mediated killing in vitro, although this may still be the case in vivo. It is important to point out that the results presented here are derived from only a single cell type (B16 and its derivatives). However, we, and others have shown that B16 cells are largely insensitive to NK cell-mediated lysis. Therefore, given the results reported here, we predict that the antitumor effects of the combination of HSVtk/GCV treatment and ACT would be even more pronounced using other tumor cell lines that are more sensitive to NK cell-mediated cytotoxicity, although further studies are required to prove such a hypothesis.
The results from our studies here also help to explain the therapeutic success that we observed in the in vivo delivery experiments where ACT of OT-1T cells was used to deliver retroviral vectors expressing the HSVtk gene to lung metastases of B16ova. 30, 31 In these studies, we observed very effective therapy with the combined ACT plus viral delivery regimen, which could not be explained simply by the added value of delivery of HSVtk retroviral vectors to about 5-10% of the tumor cells in vivo. 30 In mice lacking T cells, but significantly still retaining normal levels of NK cells, HSVtk-mediated tumor cell killing facilitated T-cell expansion in vivo such that a long-term re-population of the tumor-cured mice with the adoptively transferred OT-1T cells was observed. 30 As a direct result of these current studies, we are now progressing with those in vivo delivery studies using HSVtk gene transfer not only as a direct cytotoxic agent but, perhaps even more importantly, also in a novel context as an adjuvant to enhance the efficacy of adoptive T-cell therapy. Viewed in this context, the need to achieve very high levels of gene transfer may be less important than the immunological effects of moderately low levels of HSVtk-mediated tumor cell killing to provide immunological support for the activation and expansion of the adoptively transferred T cells.
In summary, we demonstrate that, even though only low levels of systemic HSVtk gene transfer may be currently possible in vivo, 30 and despite the several limitations of current adoptive transfer protocols, significant therapeutic benefits can be achieved by a combination of these suboptimal therapies. Moreover, for full synergism between suicide gene therapy and adoptive T-cell therapy, host NK cells are required. Therefore, therapeutic strategies aimed at maintaining NK-cell activation, even in the context of more global lymphodepletion regimens, may further enhance the potential of this combination of gene and adoptive T-cell therapies for clinical use.
Materials and methods

Cell lines
B16 melanoma (H-2k b ) expressing chicken ovalbumin gene (B16ova) was used to derive B16ovaHSVtk and B16ovaPuro. Briefly, HSVtk gene was cloned into pBabepuro retroviral plasmid and transfected into AM12 packaging cell line. 42 Supernatant from transfected AM12 was harvested, filtered using 0.45 mm filters and placed into B16ova cells. Clones were grown in dulbecco's modified eagle's medium (DMEM) and 10% fetal bovine serum (FBS), and selected on puromycin (1.25 mg ml
À1
) and G418 (5 mg ml
). B16HSVtk has been described previously. 15 
Mice
Female C57BL/6 mice and C57BL/6 RAGÀ/À mice (6-8-week old) were purchased from Jackson Laboratoriesi (Bar Harbor, ME, USA). OT-1 TCR transgenic mice that recognize SIINFEKL peptide from the chicken ovalbumin protein in the context of H À 2k b 34 were a kind gift from Dr Esteban Celis at Mayo Clinic.
Antibodies
Anti-CD8b FITC, anti-NK1.1 PE, anti-Mac-3 PE, antiCD11c PE, anti-Gr-1 PE, anti-CD45-PerCP, anti-Va2 PE, anti-IFNg APC and their respective isotype controls were purchased from BD Biosciences Pharmingen (San Diego, CA, USA).
Proliferation assay
3-(4,5-dimethylithiazol-2-yl)-2,5-diphenyl tetrazolium salt (MTT) proliferation assay from Roche Applied Sciences (Indianapolis, IN, USA) was purchased and used to determine GCV toxicity of B16ova expressing HSVtk or puro control. Briefly, 1.0 Â 10 4 cells were plated into 96-well plates in the presence or absence of GCV (5 mg ml À1 ). MTT reagent 1 (10 ml) was added and after 4 h MTT reagent 2 was added. Absorbance was read at 550 nm 1 day after the 72 h time point. cells were plated in 96-well plates with ex vivo-activated OT-1T cells at different ratios. They were incubated for 4 h at 371C in 5% CO 2 . After 4 h, 30 ml of the supernatant was collected and added to LumaPlates (PerkinElmer, Shelton, CT, USA). Percentage of lysis was determined using the following equation:
% lysis ¼ððsample lysis À spontaneousÞ= ðmaximum lysis À spontaneousÞÞ Ã 100
Hematoxylin and Eosin staining and Leukocyte infiltrates
Determination of tumor cell death/apoptosis/tissue degeneration/necrosis was carried out using hematoxylin and eosin (H&E) staining whereas tumor-infiltrating leukocytes were analyzed by flow cytometry and H&E staining as well. Tumors were harvested at indicated times from GCV-or PBS-treated mice (three mice/group) and placed in 10% neutral buffered formalin and sent for H&E staining. For flow cytometry analysis, FAC tumors were harvested (three mice/group) and submitted to flow cytometry analysis. Percentages of NK1.1+, CD45+ and Gr-1+ CD45+ and from total cells were plotted.
In vivo experiments
All procedures were approved by the Mayo Foundation Institutional Animal Care and Use Committee. Tumors were established by subcutaneous injection of 1.0 Â 10 6 B16ovaHSVtk into female C57BL/6 mice for 10 days, and treated with GCV for 5 consecutive days intraperitoneally (50 mg kg À1 ). Indicated doses of ex vivo-activated OT-1T cells were infused intravenously through the tail vain at indicated days. Tumor size was monitored every 3 days in two dimensions using a caliper. Mice were killed when tumor reached X1.0 cm in any direction or at any sign of distress or ulcers. Volume ¼ P/6(larger diameter)(smaller diameter) 2 .
Ex vivo cytotoxic T lymphocyte activation and ACT
Spleen and lymph nodes were harvested from OT-1 TCR transgenic mouse, and were made single cell suspension by standard techniques. 43 Cell suspension was treated with RBC lysing buffer, washed with PBS, counted and plated at 2.5 Â 10 of CmDiI-labeled T cells. CmDiI-labeled OT-1T cells were infused on indicated days. Tumors were harvested 1, 2 and 3 days after infusion single-cell suspensions and then stained using anti-CD3e-FITC and anti-CD45-PerCP and submitted to flow cytometry analysis.
NK cell depletion
Anti-asialo-GM1 from Cedarlane (Burlington, NC, USA) was purchased and resuspended in 1 ml. A 25 ml portion (B0.75 mg mouse
À1
) was injected intraperitoneally once before tumor inoculation, and afterwards every 5 days mice were injected with 20 ml of anti-asialo-GM1 (B0.6 mg mouse
) for a total number of six injections. Mice treated with isotype received the same protein concentration of rabbit IgG (Jackson Immuno Research Laboratories, West Grove, PA, USA). NK depletion was verified by spleen NK1.1 flow cytometry analysis.
IFNg intracellular staining
BD Cytofix/Cytoperm kit was purchased from Biosciences Pharmingen (San Diego, CA, USA) and used as described by the manufacturer. Briefly, B16ovaHSVtk tumors were established for 10 days, by injecting 1.0 Â 10 6 cells subcutaneously in mice. At day 10, mice were treated with GCV (50 mg kg À1 ) or PBS intraperitoneally for 5 consecutive days. 5.0 Â 10 6 ex vivoactivated OT-1T cells were infused intravenously 2 and 4 days after initiation of GCV treatment. Tumors were harvested (three mice/group) on day 8 after GCV initiation and placed in DMEM. These were made single cell suspension and resuspended at 2.0 Â 10 6 cells ml
À1
. PMA (50 ng ml À1 ) and ionomycin (500 ng ml À1 ) were added and incubated at 371C and 5% CO 2 for 4 h in the presence of 10 mg ml À1 brefeldin A. Cells were then washed with PBS and stained with anti-Va2-PE and anti-CD45-PERCP and submitted to intracellular staining for IFNg using antimouse IFNg-APC. Cells were gated on CD45, and the total percentages of Va2+IFNg+ were subtracted from Va2+, Isotype+ and plotted.
Statistics
Survival data from the animal studies were analyzed by the log rank test, 44 and two-sample unequal variance Student's t-test analysis was applied for in vitro assays and leukocyte infiltrate analysis. Statistical significance was determined at the level of Po0.05.
